Остеопороз и остеопатии (May 2017)

Pharmacotherapy of cardiovascular comorbidities in osteoporotic postmenopausal women

  • Nadezhda V. Izmozherova,
  • Artem A. Popov

DOI
https://doi.org/10.14341/osteo2017117-21
Journal volume & issue
Vol. 20, no. 1
pp. 17 – 21

Abstract

Read online

Aim: to assess tolerability and efficacy of cardiovascular comorbidities pharmacotherapy in osteoporotic postmenopausal women. Methods: cross-sectional study included 112 osteoporotic postmenopausal women aged from 49 to 85. Results: 95 persons (84.8%) had indications for angiotensine-convertising enzyme inhibitors (ACEI) prescription. Cough was associated with significantly higher odds of coronary heart disease, congestive heart failure and a trend to multiple bone fractures. Valsartan was initiated in 32 coughing patients. Target blood pressure level was reached in 15 women. In 15 cases blood pressure levels decreased by 30% of baseline level. Conclusion: efficacy of cardiovascular diseases in osteoporotic postmenopausal women treatment needs to be assessed in specially designed clinical trials.

Keywords